The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Target Advancement Program, 2016Protecting Dopamine Neurons in Parkinson's Disease
Study Rationale:
Parkinson's disease (PD) is caused by death of dopamine-containing cells in the brain. We discovered that a protein known as RGS6 is expressed in these cells in pre-clinical models of... -
Target Advancement Program, 2016Imaging Endogenous LRRK2 Cells
Study Rationale:
The leucine-rich repeat kinase 2 (LRRK2) protein is an important player that contributes to Parkinson's disease (PD). Unfortunately, LRRK2 is a large and complex protein that is... -
Access to Data and Biospecimens, 2016Single Molecule Detection of Oligomers in Cerebrospinal Fluid
Study Rationale:
We have developed a novel method for detecting aggregations (clumps) of proteins (specifically, alpha-synuclein) in the spinal fluid of those with Parkinson's disease (PD). We seek to... -
Therapeutic Pipeline Program, 2016Small-molecule Inhibitor to Stop Alpha-synuclein Spread for the Treatment of Parkinson's Disease
Study Rationale:
The hypothesis that misfolded alpha-synuclein (a protein associated with Parkinson's) aggregates (clumps) move from neuron-to-neuron is gaining widespread acceptance as a central... -
Improved Biomarkers and Clinical Outcome Measures, 2016Developing New Method for GBA sequencing and Detection of Germ-line or Somatic Point Mutations, Deletion/Insertions and Recombinations with the GBA Pseudo Gene
Study Rationale:
Mutations in the GBA gene are the most common genetic cause of Parkinson’s disease. This gene has a nearby pseudogene, which is a genetic material that is very...
-
Research Grant, 2016Planning Phase for a Phase IIa Study of Nilotinib in People with Parkinson's Disease
Study Rationale:
Nilotinib, a drug approved for chronic myelogenous leukemia, inhibits the protein c-Abl. Higher brain levels of c-Abl are associated with Parkinson's disease (PD), and laboratory...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.